JP2012504959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504959A5 JP2012504959A5 JP2011531018A JP2011531018A JP2012504959A5 JP 2012504959 A5 JP2012504959 A5 JP 2012504959A5 JP 2011531018 A JP2011531018 A JP 2011531018A JP 2011531018 A JP2011531018 A JP 2011531018A JP 2012504959 A5 JP2012504959 A5 JP 2012504959A5
- Authority
- JP
- Japan
- Prior art keywords
- transcription factor
- vector
- function
- polynucleotide encoding
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 45
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108091023040 Transcription factor Proteins 0.000 claims 21
- 102000040945 Transcription factor Human genes 0.000 claims 21
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 210000002865 immune cell Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 8
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 108010057988 ecdysone receptor Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 4
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims 4
- 102100035304 Lymphotactin Human genes 0.000 claims 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 IFN-α1 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 108010083702 Chemokine CCL21 Proteins 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 2
- 108700010013 HMGB1 Proteins 0.000 claims 2
- 101150021904 HMGB1 gene Proteins 0.000 claims 2
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 2
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 102100034980 ICOS ligand Human genes 0.000 claims 2
- 102100026720 Interferon beta Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010065637 Interleukin-23 Proteins 0.000 claims 2
- 108010066979 Interleukin-27 Proteins 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 2
- 108010042215 OX40 Ligand Proteins 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 102000003898 interleukin-24 Human genes 0.000 claims 2
- 108090000237 interleukin-24 Proteins 0.000 claims 2
- 108010019677 lymphotactin Proteins 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims 1
- 102100033125 Transcription factor 24 Human genes 0.000 claims 1
- 101710119682 Transcription factor 24 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10381008P | 2008-10-08 | 2008-10-08 | |
| US61/103,810 | 2008-10-08 | ||
| PCT/US2009/005510 WO2010042189A2 (en) | 2008-10-08 | 2009-10-08 | Engineered cells expressing multiple immunomodulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157352A Division JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504959A JP2012504959A (ja) | 2012-03-01 |
| JP2012504959A5 true JP2012504959A5 (https=) | 2012-11-29 |
Family
ID=42101134
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531018A Withdrawn JP2012504959A (ja) | 2008-10-08 | 2009-10-08 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2015157352A Withdrawn JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2018166324A Withdrawn JP2019000118A (ja) | 2008-10-08 | 2018-09-05 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157352A Withdrawn JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2018166324A Withdrawn JP2019000118A (ja) | 2008-10-08 | 2018-09-05 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9492482B2 (https=) |
| EP (1) | EP2356219A4 (https=) |
| JP (3) | JP2012504959A (https=) |
| KR (2) | KR101361416B1 (https=) |
| CN (1) | CN102575227A (https=) |
| AU (3) | AU2009302804B2 (https=) |
| BR (1) | BRPI0920679A2 (https=) |
| CA (1) | CA2739902A1 (https=) |
| IL (3) | IL212184A (https=) |
| MX (1) | MX340972B (https=) |
| RU (1) | RU2573912C2 (https=) |
| WO (1) | WO2010042189A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101666228B1 (ko) | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| CA2794196A1 (en) * | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| SG10201600912SA (en) * | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| CA3061802C (en) * | 2011-09-08 | 2022-04-05 | Intrexon Corporation | Crystalline diacylhydrazine and the use thereof |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| CA3101783C (en) * | 2011-10-11 | 2023-01-31 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| CN102631671B (zh) * | 2012-04-05 | 2014-11-26 | 倪国颖 | 提高疫苗诱导的细胞毒性t细胞反应的治疗性疫苗 |
| BR112015026019A2 (pt) * | 2013-04-11 | 2017-07-25 | Brigham & Womens Hospital Inc | métodos e composições de tratamento de doenças autoimunes |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| ES3011466T3 (en) * | 2013-04-18 | 2025-04-07 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CA2931322A1 (en) * | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| MY167722A (en) * | 2014-10-09 | 2018-09-21 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| SG11201704450UA (en) | 2014-12-03 | 2017-06-29 | Anaeropharma Science Inc | Coexpression plasmid |
| HUE052606T2 (hu) | 2014-12-09 | 2021-05-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| US20180112180A1 (en) * | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| EP3804741A3 (en) * | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| US20170020922A1 (en) * | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
| SG11201802912PA (en) | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| SG10201913163PA (en) | 2015-12-18 | 2020-03-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| KR20240116832A (ko) * | 2016-03-17 | 2024-07-30 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| TWI847958B (zh) * | 2016-07-05 | 2024-07-11 | 英屬開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| JP2018023343A (ja) * | 2016-08-12 | 2018-02-15 | 国立大学法人山口大学 | 細胞培養用培地、及び細胞培養方法 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR20190102259A (ko) | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| WO2018159991A1 (ko) | 2017-02-28 | 2018-09-07 | 한양대학교 산학협력단 | 종양 특이적 살상 아데노바이러스 및 면역 관문 억제제를 포함하는 항암용 조성물 |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| EP3638794A4 (en) * | 2017-06-13 | 2021-03-24 | OncoSec Medical Incorporated | MULTIGEN CONSTRUCT FOR IMMUNMODULATORY PROTEIN EXPRESSION AND METHOD OF USE |
| WO2019144945A1 (en) * | 2018-01-25 | 2019-08-01 | I-Mab | Anti-pd-l1 antibody and il-7 fusions |
| WO2019151760A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| JP2021512950A (ja) | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． | 新規なワクチンの免疫補助剤 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| WO2019173465A1 (en) | 2018-03-06 | 2019-09-12 | Intrexon Corporation | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| CA3100446A1 (en) | 2018-05-15 | 2019-11-21 | Carsgen Therapeutics Co., Ltd. | Genetically engineered cell and application thereof |
| WO2019239216A2 (en) * | 2018-06-13 | 2019-12-19 | The Council Of The Queensland Institute Of Medical Research | Viral detection assay |
| CA3103372A1 (en) * | 2018-06-27 | 2020-01-02 | Precigen, Inc. | In vivo controlled combination therapy for treatment of cancer |
| CN112823011A (zh) * | 2018-07-09 | 2021-05-18 | 加利福尼亚大学董事会 | 基于t细胞的免疫疗法的基因靶标 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| SG11202103317XA (en) | 2018-10-17 | 2021-05-28 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| TWI850282B (zh) | 2018-11-27 | 2024-08-01 | 香港商弘年發展有限公司 | 用於治療癌症之質體建構體和使用方法 |
| JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性ｈｓｖベクター |
| WO2020131656A1 (en) * | 2018-12-17 | 2020-06-25 | Immune Design Corp. | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| EP3999092A4 (en) * | 2019-07-17 | 2023-08-09 | The Regents of the University of California | Combination cancer therapy agents and methods |
| CN110354260B (zh) * | 2019-08-19 | 2020-06-26 | 启辰生生物科技(珠海)有限公司 | 免疫增强剂、药物组合物及其应用 |
| CN110732021B (zh) * | 2019-11-21 | 2020-08-25 | 北京启辰生生物科技有限公司 | 用于解除肿瘤免疫抑制的组合物及其应用 |
| EP4061485A4 (en) * | 2019-11-22 | 2023-12-20 | Alaunos Therapeutics, Inc. | METHOD FOR TREATING GLIOBLASTOMA |
| CN110904050B (zh) * | 2019-12-16 | 2021-02-05 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞、免疫调节组合物及应用 |
| CN113005090A (zh) * | 2019-12-20 | 2021-06-22 | 上海细胞治疗集团有限公司 | 共表达趋化因子和共刺激分子的dc细胞及其应用 |
| US12508309B2 (en) * | 2020-02-18 | 2025-12-30 | Vacdiagn Biotechnology Co., Ltd. | Recombinant viral vector, immunogenic composition comprising same, and uses |
| CN115867643A (zh) * | 2020-03-16 | 2023-03-28 | 布鲁塞尔自由大学 | 增强树突细胞效力的mRNA混合物 |
| CN112029730A (zh) * | 2020-05-20 | 2020-12-04 | 深圳市芥至和生物科技有限公司 | 一种基因修饰的间充质干细胞及其应用 |
| EP4163366A4 (en) * | 2020-06-09 | 2024-08-21 | Samsung Life Public Welfare Foundation | GENETICALLY MODIFIED CELL LINE FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF |
| JP2023548746A (ja) | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| CN114426585B (zh) * | 2022-02-15 | 2023-10-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
| CN115433734B (zh) * | 2022-06-01 | 2025-03-04 | 北京奇糖科技有限公司 | 核酸片段及其在制备肿瘤疫苗中的应用 |
| CN119470910A (zh) * | 2024-11-01 | 2025-02-18 | 安徽医科大学 | 一种IL-12p70蛋白在认知障碍疾病中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| DK0680517T4 (da) | 1993-01-21 | 2005-05-02 | Harvard College | Fremgangsmåde og diagnostiske sæt til bestemmelse af en forbindelses toksicitet under anvendelse afstress-promotorer fra pattedyr |
| US5698413A (en) | 1993-05-05 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of evaluating chemotherapeutic agents in vivo |
| US20040265288A1 (en) | 1995-03-08 | 2004-12-30 | Gilman Michael Z. | New applications of gene therapy technology |
| US5744304A (en) | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| US6306649B1 (en) | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
| US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| US20040086494A1 (en) | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
| CA2269642A1 (en) | 1996-10-29 | 1998-05-07 | Valentis, Inc. | Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids |
| US20040103448A1 (en) | 1997-09-05 | 2004-05-27 | Anders Bjorklund | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| DE69815707T2 (de) | 1997-11-20 | 2004-07-01 | Vical, Inc., San Diego | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
| US7279565B2 (en) | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| WO2000015264A1 (en) | 1998-09-15 | 2000-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| AU1523900A (en) | 1998-11-20 | 2000-06-13 | Valentis, Inc. | Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
| JP5031967B2 (ja) | 2000-03-22 | 2012-09-26 | イントレキソン コーポレーション | 新規エクジソン受容体ベースの誘導性遺伝子発現系 |
| CA2423093C (en) * | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
| US20030180719A1 (en) | 2001-04-13 | 2003-09-25 | Thomas Herget | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
| US20040235169A1 (en) | 2001-04-20 | 2004-11-25 | Evans Ronald M. | Inducible expression of transfected genes |
| US20030221203A1 (en) | 2001-10-03 | 2003-11-27 | Agha-Mohammadi Siamak | High efficiency regulatable gene expression system |
| RU2313365C2 (ru) * | 2001-11-29 | 2007-12-27 | Дандрит Байотек А/С | Фармацевтическая композиция для индукции иммунной реакции у человека |
| GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
| CA2502312A1 (en) | 2002-10-14 | 2004-04-29 | F. Hoffmann-La Roche Ag | Transplantable cell with immune modulator |
| CA2516320C (en) | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2004076657A2 (en) | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| WO2005033297A1 (en) | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
| US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| WO2005099773A1 (en) | 2004-04-05 | 2005-10-27 | University Of Vermont And State Agricultural College | Use of erythropoietin for treatment of cancer |
| US7704714B2 (en) | 2004-07-26 | 2010-04-27 | Agency For Science, Technology & Research | Encapsulation of cells in biologic compatible scaffolds by coacervation of charged polymers |
| US20060067942A1 (en) | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| CN101238214A (zh) | 2005-05-19 | 2008-08-06 | 拜尔先灵制药股份公司 | 使用改进的调节表达系统治疗疾病 |
| US7868159B2 (en) | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20070036770A1 (en) | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
| EP1951285A2 (en) | 2005-11-18 | 2008-08-06 | Ares Trading S.A. | Interferon in influenza |
| EP1971288B1 (en) | 2005-12-30 | 2013-02-13 | Neurotech USA, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| US20080181874A1 (en) | 2007-01-29 | 2008-07-31 | Alexander Kharazi | Cell composition and method for treating cancer |
| US20080241100A1 (en) | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
| CN104761466A (zh) | 2007-05-29 | 2015-07-08 | 英特拉克森公司 | 通过蜕皮素受体复合物调节外源性基因表达的手性二酰基肼配体 |
| WO2009009115A2 (en) | 2007-07-11 | 2009-01-15 | Nevsky Pharmaceutical Development | Liposome compositions for treatment of hepatitis c |
| WO2009025866A1 (en) | 2007-08-23 | 2009-02-26 | Intrexon Corporation | Methods and compositions for diagnosing disease |
| KR101666228B1 (ko) | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| HUE035406T2 (en) | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
| CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
-
2009
- 2009-10-08 CN CN200980150164XA patent/CN102575227A/zh active Pending
- 2009-10-08 MX MX2011003762A patent/MX340972B/es active IP Right Grant
- 2009-10-08 KR KR1020117010348A patent/KR101361416B1/ko not_active Expired - Fee Related
- 2009-10-08 EP EP09819559.7A patent/EP2356219A4/en not_active Withdrawn
- 2009-10-08 JP JP2011531018A patent/JP2012504959A/ja not_active Withdrawn
- 2009-10-08 BR BRPI0920679A patent/BRPI0920679A2/pt not_active IP Right Cessation
- 2009-10-08 AU AU2009302804A patent/AU2009302804B2/en not_active Ceased
- 2009-10-08 RU RU2011113660/10A patent/RU2573912C2/ru not_active IP Right Cessation
- 2009-10-08 KR KR1020137025903A patent/KR101629071B1/ko not_active Expired - Fee Related
- 2009-10-08 US US13/123,129 patent/US9492482B2/en not_active Expired - Fee Related
- 2009-10-08 WO PCT/US2009/005510 patent/WO2010042189A2/en not_active Ceased
- 2009-10-08 CA CA2739902A patent/CA2739902A1/en not_active Abandoned
-
2011
- 2011-04-06 IL IL212184A patent/IL212184A/en active IP Right Grant
-
2015
- 2015-08-07 JP JP2015157352A patent/JP2016025858A/ja not_active Withdrawn
- 2015-09-30 AU AU2015234302A patent/AU2015234302B2/en not_active Ceased
- 2015-10-06 US US14/876,126 patent/US20160089398A1/en not_active Abandoned
- 2015-10-25 IL IL242254A patent/IL242254A0/en unknown
-
2016
- 2016-09-26 US US15/275,943 patent/US10046049B2/en not_active Expired - Fee Related
-
2017
- 2017-05-16 AU AU2017203273A patent/AU2017203273A1/en not_active Abandoned
- 2017-08-14 IL IL253985A patent/IL253985B/en active IP Right Grant
-
2018
- 2018-05-24 US US15/988,333 patent/US20180333486A1/en not_active Abandoned
- 2018-09-05 JP JP2018166324A patent/JP2019000118A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504959A5 (https=) | ||
| JP2016025858A5 (https=) | ||
| RU2011113660A (ru) | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения | |
| Zhong et al. | Cytokines and chemokines in HBV infection | |
| Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| JP2017525364A5 (https=) | ||
| Dondeti et al. | Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms | |
| Dieu‐Nosjean et al. | Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers | |
| AU2015306231B2 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| González et al. | Tumor cell lysates as immunogenic sources for cancer vaccine design | |
| Li et al. | The interplay between inflammation and stromal components in pancreatic cancer | |
| Dobrzanski | Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| AU2018244221B2 (en) | ANK and IL-12 compositions and methods | |
| Hervas-Stubbs et al. | CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy | |
| Aivaliotis et al. | How do cytokines trigger genomic instability? | |
| Im et al. | Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| JP2010539993A5 (https=) | ||
| AU2018277294A1 (en) | Oncolytic virus and method | |
| Shen et al. | Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance | |
| Le Naour et al. | A chemically defined TLR3 agonist with anticancer activity | |
| Hoang-Le et al. | A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy | |
| Dravid et al. | Phenotype and fate of liver-resident CD8 T cells during acute and chronic hepacivirus infection |